Cargando…
Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination
BACKGROUND: Due to elderly residents, nursing homes/assisted living facilities were the most affected places in COVID-19 pandemic. Besides symptomatic patients, asymptomatic patients were detected during routine screening. AIM: This study aims to determine the factors that affect antibody response a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277604/ https://www.ncbi.nlm.nih.gov/pubmed/35829907 http://dx.doi.org/10.1007/s11845-022-03095-7 |
_version_ | 1784746019439771648 |
---|---|
author | Eren-Kutsoylu, Oya Ozlem Appak, Ozgur Nazli-Zeka, Arzu Omeroglu-Simsek, Gokcen Tekin, Nil Bayram, Basak Sayiner, Ayca Arzu Tanglay, Nesim Avkan-Oguz, Vildan |
author_facet | Eren-Kutsoylu, Oya Ozlem Appak, Ozgur Nazli-Zeka, Arzu Omeroglu-Simsek, Gokcen Tekin, Nil Bayram, Basak Sayiner, Ayca Arzu Tanglay, Nesim Avkan-Oguz, Vildan |
author_sort | Eren-Kutsoylu, Oya Ozlem |
collection | PubMed |
description | BACKGROUND: Due to elderly residents, nursing homes/assisted living facilities were the most affected places in COVID-19 pandemic. Besides symptomatic patients, asymptomatic patients were detected during routine screening. AIM: This study aims to determine the factors that affect antibody response and viral shedding in stool samples after natural exposure to the virus in residents and staff who recovered from COVID-19 before the vaccine was available. METHODS: This prospective cross-sectional study was conducted at the nation’s highest-capacity Residential and Nursing Home. Blood samples were collected between December 15, 2020 and January 15, 2021 from participating residents and staff for anti-SARS-CoV-2 antibody testing. Stool samples were obtained for SARS-CoV-2 PCR testing 2 months after COVID-19. The Social Sciences (SPSS) program version 15.0 was used for statistical analysis. The Mann–Whitney U test compared SARS‐CoV‐2 antibody concentration between two groups. RESULTS: Four hundred sixty-four (52.3%) residents and 424 (47.7%) staff participated. Entirely 259 (29.2%) participants were anti-SARS-CoV-2 IgG (+) and 255 (28.7%) were SARS-CoV-2 PCR (+). Both antibody and PCR positivity was detected in 196 (76.9%). In PCR (−) group, 63 (10.0%) participants were SARS-CoV‐2 IgG (+). Antibody titers were found highest in SARS-CoV-2 PCR (+) male residents. SARS-CoV-2 IgG titers were significantly high in SARS-CoV-2 PCR (+) and hospitalized participants regardless of age. Stool samples were obtained from 61(23.9%) participants and were found negative. CONCLUSION: A durable SARS-CoV‐2 IgG antibody response was monitored at least 9 months after the participants were diagnosed with COVID-19. SARS-CoV-2 antibody positivity was detected 76.9% in PCR (+) and 10.0% in PCR (−) participants. Knowing the duration of detectable antibodies is an important finding for developing disease prevention and public health strategies. |
format | Online Article Text |
id | pubmed-9277604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92776042022-07-14 Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination Eren-Kutsoylu, Oya Ozlem Appak, Ozgur Nazli-Zeka, Arzu Omeroglu-Simsek, Gokcen Tekin, Nil Bayram, Basak Sayiner, Ayca Arzu Tanglay, Nesim Avkan-Oguz, Vildan Ir J Med Sci Original Article BACKGROUND: Due to elderly residents, nursing homes/assisted living facilities were the most affected places in COVID-19 pandemic. Besides symptomatic patients, asymptomatic patients were detected during routine screening. AIM: This study aims to determine the factors that affect antibody response and viral shedding in stool samples after natural exposure to the virus in residents and staff who recovered from COVID-19 before the vaccine was available. METHODS: This prospective cross-sectional study was conducted at the nation’s highest-capacity Residential and Nursing Home. Blood samples were collected between December 15, 2020 and January 15, 2021 from participating residents and staff for anti-SARS-CoV-2 antibody testing. Stool samples were obtained for SARS-CoV-2 PCR testing 2 months after COVID-19. The Social Sciences (SPSS) program version 15.0 was used for statistical analysis. The Mann–Whitney U test compared SARS‐CoV‐2 antibody concentration between two groups. RESULTS: Four hundred sixty-four (52.3%) residents and 424 (47.7%) staff participated. Entirely 259 (29.2%) participants were anti-SARS-CoV-2 IgG (+) and 255 (28.7%) were SARS-CoV-2 PCR (+). Both antibody and PCR positivity was detected in 196 (76.9%). In PCR (−) group, 63 (10.0%) participants were SARS-CoV‐2 IgG (+). Antibody titers were found highest in SARS-CoV-2 PCR (+) male residents. SARS-CoV-2 IgG titers were significantly high in SARS-CoV-2 PCR (+) and hospitalized participants regardless of age. Stool samples were obtained from 61(23.9%) participants and were found negative. CONCLUSION: A durable SARS-CoV‐2 IgG antibody response was monitored at least 9 months after the participants were diagnosed with COVID-19. SARS-CoV-2 antibody positivity was detected 76.9% in PCR (+) and 10.0% in PCR (−) participants. Knowing the duration of detectable antibodies is an important finding for developing disease prevention and public health strategies. Springer International Publishing 2022-07-12 2023 /pmc/articles/PMC9277604/ /pubmed/35829907 http://dx.doi.org/10.1007/s11845-022-03095-7 Text en © The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Eren-Kutsoylu, Oya Ozlem Appak, Ozgur Nazli-Zeka, Arzu Omeroglu-Simsek, Gokcen Tekin, Nil Bayram, Basak Sayiner, Ayca Arzu Tanglay, Nesim Avkan-Oguz, Vildan Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination |
title | Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination |
title_full | Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination |
title_fullStr | Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination |
title_full_unstemmed | Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination |
title_short | Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination |
title_sort | evaluation of sars-cov-2 antibody persistence and viral spread in stool: a long-term care experience before covid-19 vaccination |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277604/ https://www.ncbi.nlm.nih.gov/pubmed/35829907 http://dx.doi.org/10.1007/s11845-022-03095-7 |
work_keys_str_mv | AT erenkutsoyluoyaozlem evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination AT appakozgur evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination AT nazlizekaarzu evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination AT omeroglusimsekgokcen evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination AT tekinnil evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination AT bayrambasak evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination AT sayineraycaarzu evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination AT tanglaynesim evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination AT avkanoguzvildan evaluationofsarscov2antibodypersistenceandviralspreadinstoolalongtermcareexperiencebeforecovid19vaccination |